467 related articles for article (PubMed ID: 32472305)
1. Pemigatinib: First Approval.
Hoy SM
Drugs; 2020 Jun; 80(9):923-929. PubMed ID: 32472305
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor.
Wu L; Zhang C; He C; Qian D; Lu L; Sun Y; Xu M; Zhuo J; Liu PCC; Klabe R; Wynn R; Covington M; Gallagher K; Leffet L; Bowman K; Diamond S; Koblish H; Zhang Y; Soloviev M; Hollis G; Burn TC; Scherle P; Yeleswaram S; Huber R; Yao W
J Med Chem; 2021 Aug; 64(15):10666-10679. PubMed ID: 34269576
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor receptor (FGFR) inhibitors: A review of a novel therapeutic class.
Weaver A; Bossaer JB
J Oncol Pharm Pract; 2021 Apr; 27(3):702-710. PubMed ID: 33375902
[TBL] [Abstract][Full Text] [Related]
4. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
Abou-Alfa GK; Sahai V; Hollebecque A; Vaccaro G; Melisi D; Al-Rajabi R; Paulson AS; Borad MJ; Gallinson D; Murphy AG; Oh DY; Dotan E; Catenacci DV; Van Cutsem E; Ji T; Lihou CF; Zhen H; Féliz L; Vogel A
Lancet Oncol; 2020 May; 21(5):671-684. PubMed ID: 32203698
[TBL] [Abstract][Full Text] [Related]
5. Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma.
Rizzo A; Ricci AD; Brandi G
Cancer Treat Res Commun; 2021; 27():100337. PubMed ID: 33611090
[TBL] [Abstract][Full Text] [Related]
6. FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement.
Patel TH; Marcus L; Horiba MN; Donoghue M; Chatterjee S; Mishra-Kalyani PS; Schuck RN; Li Y; Zhang X; Fourie Zirkelbach J; Charlab R; Liu J; Yang Y; Lemery SJ; Pazdur R; Theoret MR; Fashoyin-Aje LA
Clin Cancer Res; 2023 Mar; 29(5):838-842. PubMed ID: 36206041
[TBL] [Abstract][Full Text] [Related]
7. Pemigatinib: A Review in Advanced Cholangiocarcinoma.
Frampton JE
Target Oncol; 2024 Jan; 19(1):107-114. PubMed ID: 38206555
[TBL] [Abstract][Full Text] [Related]
8. INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models.
Liu PCC; Koblish H; Wu L; Bowman K; Diamond S; DiMatteo D; Zhang Y; Hansbury M; Rupar M; Wen X; Collier P; Feldman P; Klabe R; Burke KA; Soloviev M; Gardiner C; He X; Volgina A; Covington M; Ruggeri B; Wynn R; Burn TC; Scherle P; Yeleswaram S; Yao W; Huber R; Hollis G
PLoS One; 2020; 15(4):e0231877. PubMed ID: 32315352
[TBL] [Abstract][Full Text] [Related]
9. Infigratinib: First Approval.
Kang C
Drugs; 2021 Jul; 81(11):1355-1360. PubMed ID: 34279850
[TBL] [Abstract][Full Text] [Related]
10. Antitumor Activity of Tasurgratinib as an Orally Available FGFR1-3 Inhibitor in Cholangiocarcinoma Models With FGFR2-fusion.
Kawano S; Kawada MI; Fukushima S; Arai Y; Shibata T; Miyano SW
Anticancer Res; 2024 Jun; 44(6):2393-2406. PubMed ID: 38821585
[TBL] [Abstract][Full Text] [Related]
11. Erdafitinib: First Global Approval.
Markham A
Drugs; 2019 Jun; 79(9):1017-1021. PubMed ID: 31161538
[TBL] [Abstract][Full Text] [Related]
12. [New European approvals: Pemigatinib - cholangiocarcinoma with a FGFR2 fusion or rearrangement].
Delaye M; Pernot S
Bull Cancer; 2021 May; 108(5):446-447. PubMed ID: 33931169
[No Abstract] [Full Text] [Related]
13. [Pharmacological characteristics and clinical study results of Pemigatinib (Pemazyre
Kabu K; Takei S; Kondo M; Kitazawa K; Harada T
Nihon Yakurigaku Zasshi; 2021; 156(6):392-402. PubMed ID: 34719574
[TBL] [Abstract][Full Text] [Related]
14. Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma.
Merz V; Zecchetto C; Melisi D
Future Oncol; 2021 Feb; 17(4):389-402. PubMed ID: 33034201
[TBL] [Abstract][Full Text] [Related]
15. A drug safety evaluation of pemigatinib for advanced cholangiocarcinoma.
Uson PLS; Bearss J; Babiker HM; Borad M
Expert Opin Drug Saf; 2023; 22(8):637-641. PubMed ID: 37363820
[TBL] [Abstract][Full Text] [Related]
16. FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue.
Rizzo A; Ricci AD; Frega G; Di Federico A; Brandi G
Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):567-574. PubMed ID: 33787429
[No Abstract] [Full Text] [Related]
17. Pemigatinib in cholangiocarcinoma with a FGFR2 rearrangement or fusion.
Storandt MH; Jin Z; Mahipal A
Expert Rev Anticancer Ther; 2022 Dec; 22(12):1265-1274. PubMed ID: 36408971
[TBL] [Abstract][Full Text] [Related]
18. Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies.
Parisi A; Delaunay B; Pinterpe G; Hollebecque A; Blanc JF; Bouattour M; Assenat E; Ben Abdelghani M; Sarabi M; Niger M; Vivaldi C; Mandalà M; Palloni A; Bensi M; Garattini SK; Tougeron D; Combe P; Salati M; Rimini M; Cella CA; Tucci M; Diana A; Mori E; Longarini R; Artru P; Roth G; Evesque L; Vienne A; Turpin A; Hiret S; Bourgeois V; Herve C; Paulon R; Stacoffe M; Malka D; Neuzillet C; Edeline J; Lievre A; Guimbaud R; Chapda MCP; Rimassa L; Giampieri R; Valle J; Berardi R; Fares N
Eur J Cancer; 2024 Mar; 200():113587. PubMed ID: 38340384
[TBL] [Abstract][Full Text] [Related]
19. Clinicogenomic Analysis of
Silverman IM; Hollebecque A; Friboulet L; Owens S; Newton RC; Zhen H; Féliz L; Zecchetto C; Melisi D; Burn TC
Cancer Discov; 2021 Feb; 11(2):326-339. PubMed ID: 33218975
[TBL] [Abstract][Full Text] [Related]
20. A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality.
Jain NK; Tailang M; Thangavel N; Makeen HA; Albratty M; Najmi A; Alhazmi HA; Zoghebi K; Alagusundaram M; Jain HK; Chandrasekaran B
Acta Pharm; 2024 Mar; 74(1):1-36. PubMed ID: 38554385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]